Your session is about to expire
← Back to Search
Unknown
TDM-105795 for Male Pattern Baldness
Phase 1
Waitlist Available
Research Sponsored by Technoderma Medicines Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 days
Summary
This trial tests a new scalp solution, TDM-105795, for treating hair loss in men aged 18-55 with Androgenetic Alopecia. Participants will use the solution regularly to see if it helps grow hair or stop further loss.
Eligible Conditions
- Male Pattern Baldness
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 42 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence rate of any local and systemic AEs
Number of participants with abnormal ECG readings
Number of participants with abnormal echocardiogram results
+3 moreSecondary study objectives
Plasma concentrations of TDM-105795
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MAD Cohorts 1-4 TDM-105795 topical solutionExperimental Treatment1 Intervention
Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
Group II: Placebo for TDM-105795 topical solutionPlacebo Group1 Intervention
Multiple dose administration of Placebo forTDM-105795 Topical Solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TDM-105795
2021
Completed Phase 1
~70
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Technoderma Medicines Inc.Lead Sponsor
4 Previous Clinical Trials
183 Total Patients Enrolled
Therapeutics, Inc.Industry Sponsor
30 Previous Clinical Trials
3,880 Total Patients Enrolled
Daniel Piacquadio, M.D.Study DirectorTherapeutics Incorporated
2 Previous Clinical Trials
440 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger